Quarterly report · Q3
6960.TEDINET S100ST0Z
Period2023-04-01 → 2023-12-31
Filed2024-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥99.3bn | 2023-04-01 → 2023-12-31 | Cons. | Net sales |
| Revenue | ¥134.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥93.5bn | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Operating income | ¥19.3bn | 2023-04-01 → 2023-12-31 | Cons. | Operating income |
| Operating income | ¥16.1bn | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Ordinary income | ¥19.6bn | 2023-04-01 → 2023-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥25.1bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥16.8bn | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥19.8bn | 2023-04-01 → 2023-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥16.9bn | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥13.6bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥17.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥11.6bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥13.6bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss |
| Net income | ¥11.6bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Total assets | ¥210.7bn | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥206.9bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥195.2bn | at 2022-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥37.5bn | at 2023-12-31 | Cons. | Liabilities |
| Total liabilities | ¥43.9bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥173.2bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥163.0bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥156.6bn | at 2022-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥65.9bn | at 2023-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥68.0bn | at 2023-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥450.77 | 2023-04-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥126.46 | 2023-10-01 → 2023-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥571.25 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥383.71 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥115.28 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 82.2% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.8% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 80.2% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q3r_E02304-000Consumables And Other Productsreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥29.7bn |
| jpcrp040300-q3r_E02304-000Consumables And Other Productsreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥29.7bn |
| jpcrp040300-q3r_E02304-000Consumables And Other Productsreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥5.4bn |
| jpcrp040300-q3r_E02304-000Medical Treatment Equipmentreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥44.1bn |
| jpcrp040300-q3r_E02304-000Medical Treatment Equipmentreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥44.1bn |
| jpcrp040300-q3r_E02304-000Medical Treatment Equipmentreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥9.4bn |
| jpcrp040300-q3r_E02304-000Patient Monitoring Equipmentreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥6.0bn |
| jpcrp040300-q3r_E02304-000Patient Monitoring Equipmentreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥6.0bn |
| jpcrp040300-q3r_E02304-000Patient Monitoring Equipmentreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥1.1bn |
| jpcrp040300-q3r_E02304-000Physiological Diagnostic Equipmentreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥19.5bn |
| jpcrp040300-q3r_E02304-000Physiological Diagnostic Equipmentreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥19.5bn |
| jpcrp040300-q3r_E02304-000Physiological Diagnostic Equipmentreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥3.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-12-31 | ¥99.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-12-31 | ¥99.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-12-31 | ¥19.3bn |
| jpcrp040300-q3r_E02304-000Consumables And Other Productsreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥25.5bn |
| jpcrp040300-q3r_E02304-000Consumables And Other Productsreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥25.5bn |
| jpcrp040300-q3r_E02304-000Consumables And Other Productsreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥2.9bn |
| jpcrp040300-q3r_E02304-000Medical Treatment Equipmentreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥40.5bn |
| jpcrp040300-q3r_E02304-000Medical Treatment Equipmentreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥40.5bn |
| jpcrp040300-q3r_E02304-000Medical Treatment Equipmentreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥8.9bn |
| jpcrp040300-q3r_E02304-000Patient Monitoring Equipmentreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥7.5bn |
| jpcrp040300-q3r_E02304-000Patient Monitoring Equipmentreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥7.5bn |
| jpcrp040300-q3r_E02304-000Patient Monitoring Equipmentreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥1.2bn |
| jpcrp040300-q3r_E02304-000Physiological Diagnostic Equipmentreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥20.0bn |
| jpcrp040300-q3r_E02304-000Physiological Diagnostic Equipmentreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥20.0bn |
| jpcrp040300-q3r_E02304-000Physiological Diagnostic Equipmentreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥3.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-12-31 | ¥93.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-12-31 | ¥93.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-12-31 | ¥16.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 365
| Item | Context | Value | Unit |
|---|---|---|---|
| Description of fact that quarterly statement of cash flows has not been prepared (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |